Blog

Are generic drugs really the same as brand-name drugs?

Six common beliefs about generics tested against how FDA approval and drug pricing work, with the exceptions worth raising with a pharmacist or prescriber.

Mostly yes, and in the ways that matter for most people. A generic drug has the same active ingredient, strength, dosage form and route of administration as the brand-name drug it copies, and it must show that it delivers the drug into the body in the same way. What differs is the price history, sometimes the pill's color and filler ingredients, and occasionally the way your plan treats it. This post takes six beliefs people hold about generics, one at a time, and tests each against how the approval system and the pricing system actually work.

None of this replaces the judgment of the person who prescribes your medicine or the pharmacist who fills it. If a switch from brand to generic (or from one generic maker to another) seems to change how you feel, say so to one of them. The sections below explain why that conversation is worth having in a few specific cases and unnecessary in most.

Myth 1: "A generic has a different active ingredient, so it is a different drug"

What is true. The active ingredient, the chemical that does the work in the body, must be the same in a generic and in the brand drug it copies. So must the strength, the dosage form (tablet, capsule, injection, inhaler) and the way you take it. A generic of a 20 mg tablet is a 20 mg tablet of the same chemical.

What is not. People sometimes see a different name on the bottle and assume a different medicine. Generics are labeled with the chemical name, while the brand carries a marketing name. Lisinopril is the chemical; the brand names are trademarks. The generic drug entry covers the vocabulary, and the same idea runs through the brand-name drug definition: the brand is the first version on the market, usually protected by patents for a period.

The nuance. "Same active ingredient" is the requirement for ordinary pills and injections made from small, chemically defined molecules. It does not describe drugs made from living cells (biologics), which cannot be copied exactly. Those have follow-on products called biosimilar drugs, which are highly similar but are not generics. Myth 6 below returns to this.

Myth 2: "Generics are weaker, because the FDA lets them differ by 20 percent"

This is the most repeated claim and the most misunderstood, so it deserves the longest answer.

What the FDA actually requires. To be approved, a generic maker must show bioequivalence: that the generic releases the same amount of drug into the bloodstream, at about the same rate, as the brand. The test is usually done in a small group of healthy volunteers who take both products on different days, with blood samples taken over time. Two measurements matter, the total exposure to the drug (how much gets in) and the peak level (how high and how fast it rises).

Where the "20 percent" comes from. FDA's long-standing approach compares the generic and brand results as a ratio and requires that a statistical confidence interval around the ratio fall within a window commonly described as 80 to 125 percent. That window is a statistical tolerance for measuring a comparison with natural person-to-person and day-to-day variation. It is not permission to sell a pill that holds 80 percent of the drug. The pill must contain the labeled amount of active ingredient, and manufacturing is inspected on that basis. In practice, the average difference between an approved generic and its brand in the blood is far smaller than the window's edges. The FDA's generic drug pages explain the method for any reader who wants the technical version.

The nuance. The brand drug itself varies from batch to batch and from day to day in how a person absorbs it. A generic is tested against that normal variation, not against a fixed ideal. For most medicines this is a non-issue. For a short list of drugs with a narrow margin between a dose that works and a dose that harms, the question is more delicate. Myth 4 and the section on narrow-therapeutic-index drugs cover that.

Myth 3: "Generics work more slowly, or wear off differently"

What is true. An immediate-release generic must match the brand's pattern of getting into the blood. An extended-release generic has to match the brand's release profile too, which is a harder engineering task, so the approval standards for extended-release products include tests of the pattern over hours, not only the total.

What is not. The idea that generics are slow comes from experiences that have other explanations: a different tablet size or coating that is harder to swallow, a different release mechanism that a person feels as slightly different, or the ordinary day-to-day variation in how any medicine feels. Those experiences are real, and they are worth reporting. They are not evidence of a systematic difference.

The nuance. Some drugs are not simple pills. Inhalers, patches, creams, eye drops and injectable suspensions can differ in the device, the delivery and the way the drug reaches the target tissue, and bioequivalence is harder to measure for them. The FDA applies different tests to these products. If you use an inhaler or a patch and your pharmacy changes the product, it is reasonable to ask the pharmacist whether the device works the same way and whether you need new instructions.

Myth 4: "The pills look different, so something else must have changed"

What is true. A generic is allowed to look different from the brand. Trademark law protects the brand's shape and color, so a generic maker has to use another appearance. Inactive ingredients, such as fillers, binders, dyes and flavorings, may also differ. They are not supposed to change how the drug works, but they can matter to a person with an allergy or intolerance, for example to a dye, to lactose or to gluten in an excipient.

What is not. Different appearance does not mean different potency. It does mean that, if you have a known allergy or intolerance, you should check the ingredient list or ask the pharmacist. It also means that confusion is possible. A common safety problem is a person who takes both the old brand pills and a new generic by mistake, or who thinks a new-looking pill is wrong and stops taking it. Pharmacists get this question all the time and it is worth asking.

One more twist: several generic makers. Many generics are made by more than one company, and the pharmacy may change suppliers from one fill to the next based on price and availability. The pill can change color without anyone telling you. Ask the pharmacist to note which maker you were given if you are sensitive to a change, or to fill from the same maker when possible.

Narrow therapeutic index drugs

A small group of drugs have a narrow therapeutic index, meaning the gap between an effective blood level and a harmful or ineffective one is small, so small differences matter more. Warfarin (a blood thinner), levothyroxine (a thyroid hormone) and some anti-seizure drugs are the examples most often discussed. The FDA has applied stricter bioequivalence standards to certain narrow-therapeutic-index drugs. Even so, prescribers often like to keep a patient on one product, and blood tests are used to monitor several of these drugs because the dose is adjusted from the results.

If you take one of these medicines and your pharmacy switches the maker, the practical advice is to tell your prescriber, and to ask whether a follow-up blood test makes sense after the change. Some states also set rules on when a pharmacist may substitute for particular classes of drugs, such as anti-seizure medicines. Those rules vary, and the pharmacist or your state's board of pharmacy can tell you which apply. Nothing here is a reason to avoid generics. It is a reason to keep your prescriber informed about changes.

Myth 5: "A generic is always cheaper"

What is true. Generics usually cost far less than the brand they copy, because several makers compete once the patents and exclusivity periods end. For many common medicines, the generic price is a small fraction of the brand's list price.

What is not. Three things can break the rule.

  1. Your plan's cost sharing may not follow the drug's price. Plans sort drugs into formulary tier levels with a fixed copay or coinsurance, so a cheap generic might carry the same copay as a more expensive one. Sometimes a generic sits on a higher tier than you would expect, which the blog post Why is my cheap generic drug on a higher tier than I expected? explains in detail.
  2. The cash price can beat the insurance price. For some low-cost generics, the cash price at a pharmacy, or a discount-card price, is lower than your plan's copay. Paying cash means the purchase may not count toward your deductible, a tradeoff laid out in when paying cash for a generic beats using my insurance.
  3. Some generics are not cheap. A generic with only one or two makers, a sudden shortage, or a drug that was recently released as a generic can cost more than expected. When competition is thin, the generic price may stay close to the brand's for a time. The first generic to arrive often has a period when few competitors exist.

There is another category worth knowing: the authorized generic. This is the brand's own product sold without the brand name, often by the brand maker or a partner. It is chemically identical to the brand, including inactive ingredients, because it is the same product with a different label. It is often priced like a generic, and a plan may treat it as one.

Myth 6: "Every drug has a generic, and you can always ask for it"

What is true. A generic cannot be sold until the brand's patents and legal exclusivity periods end, and the maker of the generic has gone through FDA approval. For many drugs, particularly newer ones, no generic exists yet.

What is not. Three situations feel like "no generic" but are different.

  • The drug is a biologic. Biologics, such as many injectable drugs for arthritis, diabetes and cancer, are made in living cells and cannot be copied exactly, so the FDA approves biosimilars instead. These have their own approval standard, and a biosimilar may or may not be "interchangeable," a separate FDA designation that affects whether a pharmacist can substitute it without a new prescription. The plan may prefer one product over another for cost reasons, which the question-and-answer post My plan is switching me to a biosimilar: what should I ask? walks through.
  • A generic exists but the plan does not cover it, or covers a different one. A formulary can prefer one generic maker or one brand over another. If your generic is not covered, the process in what to do when your plan will not cover a drug you need applies.
  • A generic exists, but your prescriber wrote "dispense as written." Then the pharmacist may not substitute, and your plan may charge you more. The post What happens if I ask for the brand-name drug when a generic exists? covers what that costs.

A quick test for your own prescriptions

Put your medicines through four questions when your plan year changes or your pharmacy switches products:

  1. Is it a small-molecule pill or capsule? If yes, the bioequivalence standard above applies and substitution is routine.
  2. Is it on the narrow-therapeutic-index list or monitored with blood tests? If yes, tell your prescriber when the maker changes.
  3. Is it a device product? Inhalers, patches and injectors need a short conversation with the pharmacist about use.
  4. Is the price the one you expect? Compare the plan price, the cash price and the discount-card price before assuming. The doctor, hospital and drug network check worksheet lays the three out in one row for each medicine.

A worked, labeled illustration may help. Say a hypothetical patient fills a generic tablet each month. The plan's copay for that tier is $15. The pharmacy's cash price for the same tablet is $9, and a discount card at the same counter gives $7. If the patient is far from the deductible and pays $7 cash, the year costs 12 × $7 = $84 instead of 12 × $15 = $180, a difference of $96. If the patient expects to reach the deductible anyway, because of other care, the $84 paid in cash does not count toward it, and the picture changes. The numbers are invented round figures for the arithmetic only.

When to talk to a pharmacist, and when to talk to a prescriber

The pharmacist is the right person for questions about what the pill is, who made it, what the inactive ingredients are, how it differs in appearance, whether another generic maker is available, and what the cash price is. Pharmacists can also see whether a plan covers an alternative.

The prescriber is the right person when you think a switch changed how the drug works for you, when you take a narrow-therapeutic-index drug, when you need the brand for a medical reason, or when you want the plan to cover a brand over a generic. A medical reason for a brand, supported in writing, is the basis for an exception request.

Your plan or pharmacy benefit manager (see what pharmacy benefit managers do and why they matter and pharmacy benefit manager) is the right contact for cost questions: what tier a drug is on, whether a generic is preferred, whether a brand requires prior approval. Nobody can answer those but the plan, and the answer lives in the plan's drug list and the member portal.

What generics do not tell you

A last caution in the other direction. "Same as the brand" describes how the active ingredient behaves. It does not describe whether a drug is the right one for you, whether a newer brand is better for a condition, or whether the plan will cover it. Those are questions for you and your prescriber, and the answer may change from one year to the next as formularies change. If a covered generic and a preferred brand both exist, the cost comparison on premium, deductible, copay and coinsurance explained simply explains how the deductible and coinsurance interact with each.

Key takeaways

  • A generic must contain the same active ingredient in the same strength and form as the brand, and must pass bioequivalence testing against it. The "80 to 125 percent" figure is a statistical test window, not a permitted shortfall in the pill.
  • Different appearance and different inactive ingredients are allowed. They matter for allergies and for confusion at home, not for potency.
  • Narrow-therapeutic-index drugs, inhalers, patches and other device products deserve a conversation with the prescriber or pharmacist when the product changes.
  • A generic is usually, but not always, cheaper. Tier placement, shortages, thin competition and cash or discount-card prices can reverse the order, so compare the actual prices.
  • Biologics have biosimilars rather than generics, and a plan can steer you toward one or the other for cost reasons. Ask the plan and your prescriber, and look up the exact drug in the plan's drug list.

Terms used in this guide

Related tools

Related guides

Latest on this topic